ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

CRIS Curis Inc

14.47
-0.05 (-0.34%)
27 4월(4) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Curis Inc CRIS 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
-0.05 -0.34% 14.47 09:00:00
개장가 저가 고가 종가 전일 종가
14.44 14.25 14.6899 14.47 14.52
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
05/04/202420:30PRNUSCuris Reports Inducement Grants Under NASDAQ Listing Rule..
04/04/202420:30PRNUSCuris to Present at Upcoming Healthcare Conferences in April
13/02/202406:16EDGAR2Form SC 13G - Statement of acquisition of beneficial..
09/02/202406:36EDGAR2Form S-8 - Securities to be offered to employees in employee..
09/02/202406:27EDGAR2Form S-3 - Registration statement under Securities Act of..
09/02/202406:01EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
08/02/202422:01EDGAR2Form 8-K - Current report
08/02/202422:00PRNUSCuris Provides Fourth Quarter 2023 Business Update
01/02/202422:00PRNUSCuris to Release Fourth Quarter 2023 Financial Results and..
11/01/202422:13EDGAR2Form 8-K - Current report
05/01/202422:00PRNUSCuris Reports Inducement Grants Under NASDAQ Listing Rule..
22/12/202306:00EDGAR2Form 10-K/A - Annual report [Section 13 and 15(d), not S-K..
12/12/202322:00PRNUSCuris Announces Initial Combination Study Data from its..
11/12/202322:00PRNUSCuris Presented Clinical Data from the TakeAim Leukemia..
06/12/202322:00PRNUSCuris Announces Three Presentations at ASH
05/12/202322:00PRNUSCuris Enters into Agreement for Emavusertib / Pembrolizumab..
02/11/202321:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202321:01EDGAR2Form 8-K - Current report
02/11/202321:00PRNUSCuris Provides Third Quarter 2023 Business Update
26/10/202321:30PRNUSCuris to Release Third Quarter 2023 Financial Results and..
06/10/202321:56PRNUSCuris Reports Inducement Grants Under NASDAQ Listing Rule..
29/09/202305:05EDGAR2Form 8-K/A - Current report: [Amend]
28/09/202321:54EDGAR2Form 8-K - Current report
12/09/202321:00PRNUSCuris Announces Date for the 2nd Symposium on IRAK4 in..
06/09/202321:13PRNUSCuris to Present at Upcoming Healthcare Conferences in..
19/08/202305:02EDGAR2Form DEF 14A - Other definitive proxy statements
05/08/202305:09EDGAR2Form PRE 14A - Other preliminary proxy statements
04/08/202305:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
04/08/202305:02EDGAR2Form 8-K - Current report
04/08/202305:01PRNUSCuris Provides Second Quarter 2023 Business Update
28/07/202307:25PRNUSCuris to Release Second Quarter 2023 Financial Results and..
07/07/202305:30EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/07/202322:28EDGAR2Form 8-K - Current report
06/07/202321:04EDGAR2Form 8-K - Current report
06/07/202321:01PRNUSFDA Removes Partial Clinical Hold on TakeAim Leukemia Study..
06/07/202321:00PRNUSCuris Announces $15.1 Million Registered Direct Offering
05/05/202320:30PRNUSCuris Reports Inducement Grants Under NASDAQ Listing Rule..
05/05/202305:01PRNUSCuris Provides First Quarter 2023 Business Update

최근 히스토리

Delayed Upgrade Clock